<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507297</url>
  </required_header>
  <id_info>
    <org_study_id>1K23HL122461-01A1</org_study_id>
    <nct_id>NCT02507297</nct_id>
  </id_info>
  <brief_title>Sleep-Disordered Breathing and PAP in Perinatal Depression</brief_title>
  <official_title>Sleep-Disordered Breathing and PAP in Perinatal Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to understand the contribution of sleep-disordered breathing (SDB)&#xD;
      to one of the most common and debilitating adverse pregnancy outcomes, perinatal depression.&#xD;
      The study is a randomized trial to test the efficacy of positive airway pressure (PAP) on&#xD;
      sleep and depression symptoms in perinatal women. Participants will be pregnant women with&#xD;
      depression and sleep-disordered breathing. Participants will be randomly assigned to receive&#xD;
      either PAP therapy (PAP group) or treatment as usual within obstetrics (TAU group). Mood and&#xD;
      sleep assessments will be completed at baseline, after 1 week of enrollment, and monthly&#xD;
      thereafter through 12 weeks postpartum. Cortisol will be measured using saliva collection at&#xD;
      baseline and again 8 weeks later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">April 25, 2020</completion_date>
  <primary_completion_date type="Actual">April 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item</measure>
    <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
    <description>Change in clinician-rated depression severity and symptoms, excluding the items which measure sleep. Total score range: 0-46. Higher scores represent more severe depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Edinburgh Postnatal Depression Scale Score</measure>
    <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
    <description>Change in a self-report measure of depression symptoms and severity. Total scores range from 0 to 27; higher scores indicate more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pittsburgh Sleep Quality Index Score</measure>
    <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
    <description>Change in a measure of sleep quality. Total scores range from 0 to 21. Higher scores indicate worse sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS) Score</measure>
    <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
    <description>Change in a measure of excessive daytime sleepiness. Scores range from 0 to 25. Higher scores indicate more daytime sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Salivary Cortisol</measure>
    <time_frame>Baseline to 8 weeks after baseline</time_frame>
    <description>Salivary cortisol is a hormone produced by the adrenal gland. Values are in nmol/L; detectable assay range is 0.33 - 82.77 nmol/L. Higher values indicate higher levels of cortisol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Sleep-disordered Breathing</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>PAP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment as usual through obstetrics</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positive Airway Pressure (PAP)</intervention_name>
    <description>Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
    <arm_group_label>PAP Group</arm_group_label>
    <other_name>CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-32 weeks gestation with a single, live fetus&#xD;
&#xD;
          -  meet criteria for major depressive disorder per the Structured Clinical Interview for&#xD;
             DSM-V (SCID)&#xD;
&#xD;
          -  respiratory distress index (RDI; includes apneas, hypopneas, and respiratory&#xD;
             effort-related arousals)≥5 per ambulatory assessment plus apnea symptoms (snoring,&#xD;
             witnessed apnea, daytime sleepiness, sleep disturbance, snort arousals)&#xD;
&#xD;
          -  stable dose (for ≥8 weeks) of a selective serotonin reuptake inhibitor (SSRI) OR free&#xD;
             of all antidepressant medications past 4 weeks&#xD;
&#xD;
          -  obstetrics care is at the University of Michigan, and the woman plans on delivering&#xD;
             her baby at the University of Michigan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of bipolar disorder, posttraumatic stress disorder, schizophrenia or&#xD;
             psychosis, dissociative disorders, eating disorder, obsessive-compulsive disorder,&#xD;
             somatic symptom and related disorders, substance use disorder, panic disorder,&#xD;
             agoraphobia per DSM-V&#xD;
&#xD;
          -  diagnosis of, or suspicion for, narcolepsy or REM behavior disorder&#xD;
&#xD;
          -  current SDB treatment; medical conditions for which PAP is contraindicated (e.g.,&#xD;
             pneumothorax, pneumocephalus, recent trauma, recent surgery)&#xD;
&#xD;
          -  evidence of risk for drowsy driving (excessive daytime sleepiness plus history of&#xD;
             motor vehicle accident or near miss due to sleepiness, fatigue, or inattention in past&#xD;
             12 months).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Swanson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <results_first_submitted>April 20, 2021</results_first_submitted>
  <results_first_submitted_qc>April 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Leslie Swanson</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02507297/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PAP Group</title>
          <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
        </group>
        <group group_id="P2">
          <title>TAU Group</title>
          <description>Treatment as usual through obstetrics</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PAP Group</title>
          <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
        </group>
        <group group_id="B2">
          <title>TAU Group</title>
          <description>Treatment as usual through obstetrics</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.44" spread="5.39"/>
                    <measurement group_id="B2" value="27.31" spread="6.32"/>
                    <measurement group_id="B3" value="29.18" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Rating Scale for Depression (HRSD) Score, Excluding the Sleep Items</title>
          <description>Clinician-rated depression severity and symptoms, excluding the items which measure sleep. Total score range: 0-46. Higher scores represent more severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.06" spread="3.87"/>
                    <measurement group_id="B2" value="14.69" spread="3.68"/>
                    <measurement group_id="B3" value="14.9" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Edinburgh Postnatal Depression Scale (EPDS) Score, Minus the Sleep Item</title>
          <description>Self-reported measure of depression symptoms and severity, minus the sleep item. Total scores range from 0 to 27; higher scores indicate more severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.88" spread="3.79"/>
                    <measurement group_id="B2" value="14.15" spread="3.76"/>
                    <measurement group_id="B3" value="12.9" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pittsburgh Sleep Quality Index (PSQI) Score</title>
          <description>Measure of sleep quality. Total scores range from 0 to 21. Higher scores indicate worse sleep quality.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.93" spread="2.82"/>
                    <measurement group_id="B2" value="10.76" spread="3.36"/>
                    <measurement group_id="B3" value="10.38" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epworth Sleepiness Scale (ESS) Score</title>
          <description>Measure of excessive daytime sleepiness. Scores range from 0 to 25. Higher scores indicate more daytime sleepiness.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.47" spread="4.17"/>
                    <measurement group_id="B2" value="9.41" spread="4.17"/>
                    <measurement group_id="B3" value="11.03" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Salivary cortisol</title>
          <description>Salivary cortisol is a hormone produced by the adrenal gland. Values are in nmol/L; detectable assay range is 0.33 - 82.77 nmol/L. Higher values indicate higher levels of cortisol.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.07" spread="6.89"/>
                    <measurement group_id="B2" value="33.02" spread="10.82"/>
                    <measurement group_id="B3" value="33.05" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item</title>
        <description>Change in clinician-rated depression severity and symptoms, excluding the items which measure sleep. Total score range: 0-46. Higher scores represent more severe depression.</description>
        <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
        <population>For baseline to 12 weeks postpartum, data are not available for 2 participants in the TAU group and 2 participants in the PAP group.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP Group</title>
            <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
          </group>
          <group group_id="O2">
            <title>TAU Group</title>
            <description>Treatment as usual through obstetrics</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item</title>
          <description>Change in clinician-rated depression severity and symptoms, excluding the items which measure sleep. Total score range: 0-46. Higher scores represent more severe depression.</description>
          <population>For baseline to 12 weeks postpartum, data are not available for 2 participants in the TAU group and 2 participants in the PAP group.</population>
          <units>change in score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 weeks after baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.14" spread="5.77"/>
                    <measurement group_id="O2" value="-5.92" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks postpartum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.21" spread="7.39"/>
                    <measurement group_id="O2" value="-6.18" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks after baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.242</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks postpartum</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.48</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Edinburgh Postnatal Depression Scale Score</title>
        <description>Change in a self-report measure of depression symptoms and severity. Total scores range from 0 to 27; higher scores indicate more severe depression.</description>
        <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
        <population>Data for the baseline to 8 weeks after baseline analysis are not available for 1 participant in the PAP group. Data for the baseline to 12 weeks postpartum analysis are not available for 3 participants in the TAU group and for 2 participants in the PAP group.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP Group</title>
            <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
          </group>
          <group group_id="O2">
            <title>TAU Group</title>
            <description>Treatment as usual through obstetrics</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Edinburgh Postnatal Depression Scale Score</title>
          <description>Change in a self-report measure of depression symptoms and severity. Total scores range from 0 to 27; higher scores indicate more severe depression.</description>
          <population>Data for the baseline to 8 weeks after baseline analysis are not available for 1 participant in the PAP group. Data for the baseline to 12 weeks postpartum analysis are not available for 3 participants in the TAU group and for 2 participants in the PAP group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 weeks after baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.93" spread="3.13"/>
                    <measurement group_id="O2" value="-2.23" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks postpartum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="3.88"/>
                    <measurement group_id="O2" value="-5.00" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks after baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.136</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks postpartum</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.324</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pittsburgh Sleep Quality Index Score</title>
        <description>Change in a measure of sleep quality. Total scores range from 0 to 21. Higher scores indicate worse sleep quality.</description>
        <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
        <population>Data for four participants from the PAP group are not available in the baseline to 8 weeks after baseline analysis, and data from three participants from the TAU group and two participants in the PAP group are not available in the baseline to 12 weeks analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP Group</title>
            <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
          </group>
          <group group_id="O2">
            <title>TAU Group</title>
            <description>Treatment as usual through obstetrics</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pittsburgh Sleep Quality Index Score</title>
          <description>Change in a measure of sleep quality. Total scores range from 0 to 21. Higher scores indicate worse sleep quality.</description>
          <population>Data for four participants from the PAP group are not available in the baseline to 8 weeks after baseline analysis, and data from three participants from the TAU group and two participants in the PAP group are not available in the baseline to 12 weeks analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 weeks after baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="3.49"/>
                    <measurement group_id="O2" value="-0.385" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks postpartum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="3.67"/>
                    <measurement group_id="O2" value="-1.8" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks after baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.291</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks postpartum</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.752</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Epworth Sleepiness Scale (ESS) Score</title>
        <description>Change in a measure of excessive daytime sleepiness. Scores range from 0 to 25. Higher scores indicate more daytime sleepiness.</description>
        <time_frame>Baseline to 8 weeks after baseline, and at 12 weeks postpartum</time_frame>
        <population>Data are not available for 3 participants in the PAP group at baseline to 8 weeks and 2 participants in the PAP group at baseline to 12 weeks postpartum. Data are not available for 3 participants in the TAU group at baseline to 12 weeks postpartum.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP Group</title>
            <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
          </group>
          <group group_id="O2">
            <title>TAU Group</title>
            <description>Treatment as usual through obstetrics</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Epworth Sleepiness Scale (ESS) Score</title>
          <description>Change in a measure of excessive daytime sleepiness. Scores range from 0 to 25. Higher scores indicate more daytime sleepiness.</description>
          <population>Data are not available for 3 participants in the PAP group at baseline to 8 weeks and 2 participants in the PAP group at baseline to 12 weeks postpartum. Data are not available for 3 participants in the TAU group at baseline to 12 weeks postpartum.</population>
          <units>change in score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 weeks after baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="3.26"/>
                    <measurement group_id="O2" value="1.08" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks postpartum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="4.15"/>
                    <measurement group_id="O2" value="-1" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks after baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.155</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks postpartum</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.568</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Salivary Cortisol</title>
        <description>Salivary cortisol is a hormone produced by the adrenal gland. Values are in nmol/L; detectable assay range is 0.33 - 82.77 nmol/L. Higher values indicate higher levels of cortisol.</description>
        <time_frame>Baseline to 8 weeks after baseline</time_frame>
        <population>Data are not available for 4 participants in the PAP group and 3 participants in the TAU group.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP Group</title>
            <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
          </group>
          <group group_id="O2">
            <title>TAU Group</title>
            <description>Treatment as usual through obstetrics</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Salivary Cortisol</title>
          <description>Salivary cortisol is a hormone produced by the adrenal gland. Values are in nmol/L; detectable assay range is 0.33 - 82.77 nmol/L. Higher values indicate higher levels of cortisol.</description>
          <population>Data are not available for 4 participants in the PAP group and 3 participants in the TAU group.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="7.23"/>
                    <measurement group_id="O2" value="1.38" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.486</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from randomization until participants reached 12 weeks postpartum (the final time point in the study).</time_frame>
      <desc>Participants were queried about adverse events each time they completed the clinical assessment (Hamilton Rating Scale for Depression). Adverse event information was also obtained from participants' medical records.&#xD;
Note that participants in the TAU group were not at risk for the adverse events related to positive airway pressure (PAP) treatment as they were not assigned to receive PAP treatment; these adverse events are denoted by a 0 in the denominator for at risk designation for TAU group.</desc>
      <group_list>
        <group group_id="E1">
          <title>PAP Group</title>
          <description>Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly&#xD;
Positive Airway Pressure (PAP): Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.</description>
        </group>
        <group group_id="E2">
          <title>TAU Group</title>
          <description>Treatment as usual through obstetrics</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <description>Hyperbilirubinemia in participant's infant requiring hospitalization of infant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postpartum hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Dry mouth specifically related to CPAP usage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Insomnia specifically related to using CPAP or to in-lab sleep night (only PAP participants completed the in-lab sleep night)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <description>Gestational diabetes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Small for gestational age (infant)</sub_title>
                <description>Participant's infant was small for gestational age</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <description>Claustrophobia when using CPAP mask</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Worsening of depression from baseline</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Distress/anxiety in completing study questionnaires</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Nasal congestion specifically related to CPAP usage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <description>Skin irritation specifically related to CPAP mask</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leslie Swanson</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-764-2242</phone>
      <email>lmswan@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

